This website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
This Website Uses Cookies By closing this message or continuing to use our site, you agree to our cookie policy. Learn MoreThis website requires certain cookies to work and uses other cookies to help you have the best experience. By visiting this website, certain cookies have already been set, which you may delete and block. By closing this message or continuing to use our site, you agree to the use of cookies. Visit our updated privacy and cookie policy to learn more.
he U.S. Department of Justice’s Consumer Protection Branch has launched a criminal investigation against Abbott Nutrition due to the 2022 foodborne illness outbreak linked to powdered infant formula manufactured at the company’s Sturgis, Michigan facility.
The U.S. Food and Drug Administration (FDA) has concluded its internal review of the agency’s response to the U.S. infant formula supply crisis, which details key findings and recommendations that will allow the agency to respond more quickly during food safety emergencies.
In light of the current infant formula supply shortage, the U.S. Food and Drug Administration (FDA) will enter a consent decree with Abbott Nutrition that will allow the company to resume production of formula products at its Sturgis, Michigan facility. FDA also released a guidance that will allow formula manufacturers and importers greater flexibility.